SUCLG2 and colonic neoplasm: In colon cancer, the expressions of SUCLG2 and SUCLG2P2 are reduced, the competitive binding hsa-miR-588 is reduced, hsa-miR-588 is increased, and hsa-miR-588 exerts a tumor suppressor effect.